Matejka Rebolj

Matejka Rebolj

Auto-generated profile, based on publicly available information

Matejka Rebolj

Queen Mary University of London

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2019 in BMJ
Verified
Journal Article
Open access
PDF file
MRMatejka Rebolj
Matejka Rebolj
JRJanet Rimmer
Janet Rimmer
KDKarin Denton
Karin Denton
JTJohn Tidy
John Tidy
CMChristopher Mathews
Christopher Mathews
HKHenry Kitchener
Henry Kitchener
Objective To provide the first report on the main outcomes from the prevalence and incidence rounds of a large pilot of routine primary high risk human papillomavirus (hrHPV) testing in England, compared with contemporaneous primary liquid based cytology screening. Design Observational study. Setting The English Cervical Screening Programme. Participants 578 547 women undergoing cervical screening in primary care between May 2013 and December 2014, with follow-up until May 2017; 183 970 (32%) were screened with hrHPV testing. Interventions Routine cervical screening with hrHPV testing with liquid based cytology triage and two early recalls for women who were hrHPV positive and cytology negative, following the national screening age and interval recommendations. Main outcome measures Frequency of referral for a colposcopy; adherence to early recall; and relative detection of cervical intraepithelial neoplasia grade 2 or worse from hrHPV testing compared with liquid based cytology in two consecutive screening rounds. Results Baseline hrHPV testing and early recall required approximately 80% more colposcopies, (adjusted odds ratio 1.77, 95% confidence interval 1.73 to 1.82), but detected substantially more cervical intraepithelial neoplasia than liquid based cytology (1.49 for cervical intraepithelial neoplasia grade 2 or worse, 1.43 to 1.55; 1.44 for cervical intraepithelial neoplasia grade 3 or worse, 1.36 to 1.51) and for cervical cancer (1.27, 0.99 to 1.63). Attendance at early recall and colposcopy referral were 80% and 95%, respectively. At the incidence screen, the 33 506 women screened with hrHPV testing had substantially less cervical intraepithelial neoplasia grade 3 or worse than the 77 017 women screened with liquid based cytology (0.14, 0.09 to 0.23). Conclusions In England, routine primary hrHPV screening increased the detection of cervical intraepithelial neoplasia grade 3 or worse and cervical cancer by approximately 40% and 30%, respectively, compared with liquid based cytology. The very low incidence of cervical intraepithelial neoplasia grade 3 or worse after three years supports extending the screening interval.

8 May 2018 in British Journal of Cancer
Verified
Journal Article
Open access
MRMatejka Rebolj
Matejka Rebolj
VAValentina Assi
Valentina Assi
ABAdam Brentnall
Adam Brentnall
DPDharmishta Parmar
Dharmishta Parmar
SDStephen W. Duffy
Stephen W. Duffy
Mammography is less effective in detecting cancer in dense than in fatty breasts. We undertook a systematic search in PubMed to identify studies on women with dense breasts who underwent screening with mammography supplemented with ultrasound. A meta-analysis was undertaken on the proportion of cancers detected only by ultrasound, out of all screen-detected cancers, and the proportion of women with negative mammography who were referred for assessment following ultrasound screening. Twenty-nine studies satisfied our inclusion criteria. The proportion of total cancers detected only by ultrasound was 0.29 (95% CI: 0.27-0.31), consistent with an approximately 40% increase in the detection of cancers compared to mammography. In the studied populations, this translated into an additional 3.8 (95% CI: 3.4-4.2) screen-detected cases per 1000 mammography-negative women. About 13% (32/248) of cancers were in situ from 17 studies with information on this subgroup. Ultrasound approximately doubled the referral for assessment in three studies with these data. Studies have consistently shown an increased detection of breast cancer by supplementary ultrasound screening. An inclusion of supplementary ultrasound into routine screening will need to consider the availability of ultrasound and diagnostic assessment capacities.

31 January 2014 in Journal of Medical Screening
Verified
Journal Article
Open access
JLJanni Uyen Hoa Lam
Janni Uyen Hoa Lam
MRMatejka Rebolj
Matejka Rebolj
PDPierre-Antoine Dugue
Pierre-Antoine Dugue
JBJesper Bonde
Jesper Bonde
MEMy von Euler-Chelpin
My von Euler-Chelpin
ELElsebeth Lynge
Elsebeth Lynge
Objectives: Based on cross-sectional studies, the data on protection from Human Papillomavirus (HPV) infections related to using male condoms appear inconsistent. Longitudinal studies are more informative for this purpose. We undertook a systematic review of longitudinal studies on the effectiveness of male condoms in preventing HPV infection and cervical neoplasia. Methods: We searched PubMed using MeSH terms for articles published until May 2013. Articles were included if they studied a change in non-immunocompromized women’s cervical HPV infection or cervical lesion status along with the frequency of condom use. Results: In total, 384 abstracts were retrieved. Eight studies reported in 10 articles met the inclusion criteria for the final review. Four studies showed a statistically significantly protective effect of consistent condom use on HPV infection and on regression of cervical neoplasia. In the remaining four studies, a protective effect was also observed for these outcomes, although it was not statistically significant. Conclusions: Consistent condom use appears to offer a relatively good protection from HPV infections and associated cervical neoplasia. Advice to use condoms might be used as an additional instrument to prevent unnecessary colposcopies and neoplasia treatments in cervical screening, and to reduce the risk of cervical cancer.

20 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MRMatejka Rebolj
Matejka Rebolj
SPSarah Preisler
Sarah Preisler
DEDitte Møller Ejegod
Ditte Møller Ejegod
CRCarsten Rygaard
Carsten Rygaard
ELElsebeth Lynge
Elsebeth Lynge
JBJesper Bonde
Jesper Bonde
We aimed to determine the disagreement in primary cervical screening between four human papillomavirus assays: Hybrid Capture 2, cobas, CLART, and APTIMA. Material from 5,064 SurePath samples of women participating in routine cervical screening in Copenhagen, Denmark, was tested with the four assays. Positive agreement between the assays was measured as the conditional probability that the results of all compared assays were positive given that at least one assay returned a positive result. Of all 5,064 samples, 1,679 (33.2%) tested positive on at least one of the assays. Among these, 41% tested positive on all four. Agreement was lower in women aged ≥30 years (30%, vs. 49% at <30 years), in primary screening samples (29%, vs. 38% in follow-up samples), and in women with concurrent normal cytology (22%, vs. 68% with abnormal cytology). Among primary screening samples from women aged 30–65 years (n = 2,881), 23% tested positive on at least one assay, and 42 to 58% of these showed positive agreement on any compared pair of the assays. While 4% of primary screening samples showed abnormal cytology, 6 to 10% were discordant on any pair of assays. A literature review corroborated our findings of considerable disagreement between human papillomavirus assays. This suggested that the extent of disagreement in primary screening is neither population- nor storage media-specific, leaving assay design differences as the most probable cause. The substantially different selection of women testing positive on the various human papillomavirus assays represents an unexpected challenge for the choice of an assay in primary cervical screening, and for follow up of in particular HPV positive/cytology normal women.

13 September 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
PDPierre-Antoine Dugue
Pierre-Antoine Dugue
MRMatejka Rebolj
Matejka Rebolj
JHJesper Hallas
Jesper Hallas
PGPeter Garred
Peter Garred
ELElsebeth Lynge
Elsebeth Lynge
Severely immunosuppressed individuals have a strongly increased risk of cervical cancer. In patients with autoimmune diseases (AID), who have defects in their immune system and receive immunosuppressants, the risk of cervical cancer is less clear. We conducted a cohort study, using Danish nationwide population‐based registers including information on AID diagnoses, immunosuppressant intake, cervical screening participation, and cervical cancer incidence. Standardized incidence ratios (SIR) were computed to compare the risk of cervical cancer in AID patients to that of the general population. Hazard ratios (HR) from time‐dependent Cox models stratified by AID were used to explore the effect of the most frequently used immunosuppressants, taking into account potential dose–response relationships and lag times between drug exposure and cervical cancer development. Cervical screening coverage of patients with AIDs was compared to the general population. Among 341,758 patients with AIDs, the risk of cervical cancer was not higher than in the general population (SIR = 1.0, 95% CI: 0.9–1.1, based on 720 cases). The intake of immunosuppressants was generally not associated with the risk, apart from azathioprine. The crude HR comparing the period of exposure versus non‐exposure to azathioprine was 1.4 (95% CI: 0.9–2.1). Furthermore, the risk was substantially increased in patients who received a high cumulative dose of azathioprine (HR = 2.2, 95% CI = 1.2–3.9), and appeared to be highest when considering that the immunosuppressant exposure would take 5 years to trigger cervical cancer. Patients with AIDs had similarly high screening rates as the general population. Although most patients with AIDs do not have an increased risk of cervical cancer, those taking substantial amounts of azathioprine might need more stringent cervical screening measures.

21 July 2014 in APMIS
Verified
Journal Article
Closed access
PDF file
ELElsebeth Lynge
Elsebeth Lynge
CRCarsten Rygaard
Carsten Rygaard
MBMiguel Vazquez‐Prada Baillet
Miguel Vazquez‐Prada Baillet
PDPierre-Antoine Dugue
Pierre-Antoine Dugue
BSBente Braad Sander
Bente Braad Sander
MRMatejka Rebolj
Matejka Rebolj